We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

241 hedge funds and large institutions have $4.88B invested in Intra-Cellular Therapies Inc. in 2022 Q1 according to their latest regulatory filings, with 66 funds opening new positions, 90 increasing their positions, 64 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more first-time investments, than exits

New positions opened: 66 | Existing positions closed: 31

106% more call options, than puts

Call options by funds: $33.7M | Put options by funds: $16.4M

63% more funds holding in top 10

Funds holding in top 10: 8 → 13 (+5)

41% more repeat investments, than reductions

Existing positions increased: 90 | Existing positions reduced: 64

36% more capital invested

Capital invested by funds: $3.59B → $4.88B (+$1.29B)

16% more funds holding

Funds holding: 208 → 241 (+33)

Holders
241
Holders Change
+33
Holders Change %
+15.87%
% of All Funds
3.8%
Holding in Top 10
13
Holding in Top 10 Change
+5
Holding in Top 10 Change %
+62.5%
% of All Funds
0.21%
New
66
Increased
90
Reduced
64
Closed
31
Calls
$33.7M
Puts
$16.4M
Net Calls
+$17.3M
Net Calls Change
-$19.4M

Top Buyers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
+$211M
2
Victory Capital Management
Victory Capital Management
Texas
+$48.4M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$47.4M
4
BlackRock
BlackRock
New York
+$38.9M
5
Holocene Advisors
Holocene Advisors
New York
+$37.5M

Top Sellers

Rank Fund Capital Flow
1
WA
Wasatch Advisors
Utah
-$39.3M
2
SC
Samlyn Capital
New York
-$32.5M
3
TCM
TimesSquare Capital Management
New York
-$24.2M
4
Two Sigma Investments
Two Sigma Investments
New York
-$14.5M
5
EP
Eversept Partners
New York
-$12.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
EI
101
EAM Investors
California
$2.47M -$108K -2,074 -5%
CM
102
Castleark Management
Illinois
$2.46M +$2.09M +40,270 New
IHAM
103
Integral Health Asset Management
New York
$2.45M +$2.08M +40,000 New
AIG
104
American International Group
New York
$2.44M +$121K +2,339 +6%
T. Rowe Price Associates
105
T. Rowe Price Associates
Maryland
$2.43M +$182K +3,513 +10%
EAM
106
EFG Asset Management
Oregon
$2.37M -$18K -346 -0.9%
CCIA
107
Campbell & Co Investment Adviser
Maryland
$2.32M +$1.97M +37,863 New
Barclays
108
Barclays
United Kingdom
$2.31M -$3.38M -65,138 -63%
CS
109
Candriam SCA
Luxembourg
$2.2M -$4.24M -81,710 -69%
BMSSC
110
B. Metzler seel. Sohn & Co
Germany
$2.17M +$187K +3,600 +11%
AI
111
Atom Investors
Texas
$2.1M +$348K +6,707 +24%
Manulife (Manufacturers Life Insurance)
112
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2M -$90.8K -1,749 -5%
B
113
Bailard
California
$1.97M – – –
Jane Street
114
Jane Street
New York
$1.97M -$432K -8,315 -21%
Balyasny Asset Management
115
Balyasny Asset Management
Illinois
$1.96M +$1.66M +31,967 New
MC
116
Miramar Capital
Illinois
$1.74M +$1.48M +28,445 New
JIP
117
Jaffetilchin Investment Partners
Florida
$1.73M -$44.9K -864 -3%
State Board of Administration of Florida Retirement System
118
State Board of Administration of Florida Retirement System
Florida
$1.69M – – –
GL
119
Graypoint LLC
New York
$1.62M +$1.37M +26,436 New
BC
120
Brookfield Corp
Ontario, Canada
$1.56M +$1.33M +25,540 New
ProShare Advisors
121
ProShare Advisors
Maryland
$1.51M -$118K -2,280 -8%
Osaic Holdings
122
Osaic Holdings
Arizona
$1.5M +$1.2M +23,017 +1,468%
OAM
123
Oppenheimer Asset Management
New York
$1.46M +$264K +5,088 +27%
CSS
124
Cubist Systematic Strategies
Connecticut
$1.44M +$1.22M +23,562 New
SG
125
Stonnington Group
California
$1.43M +$917K +17,650 +350%
3 4
5
6 7

ITCI Hedge Fund Activity: Q1 2022 in Review

241 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2022, worth a combined $4.88B — up 36% from $3.59B a quarter earlier.

Buyers outnumbered sellers: 66 funds opened new ITCI positions and 31 closed out — a net gain of 35 holders — while 90 added to existing stakes and 64 trimmed.

The largest buyer was Wellington Management Group, opening a new position worth an estimated $211M. The largest seller was Wasatch Advisors, cutting an estimated $39.3M.

  • 241 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2022, up from 208 in Q4 2021.
  • Funds reported $4.88B of Intra-Cellular Therapies Inc. stock for Q1 2022, up 36% quarter-over-quarter.
  • 66 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2022 and 31 closed out, a net change of +35 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q1 2022 was Wellington Management Group, an estimated $211M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q1 2022 was Wasatch Advisors, an estimated $39.3M sold.

Based on aggregated 13F filings for Q1 2022.